Exploration of endocrine-disrupting chemicals on estrogen receptor α by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-Adamantyl)phenol as a potent endocrine disruptor candidate

Toxicology Letters

Volumn 191, Issue 1, 2009, Pages 33-39

  Nose, Takeru ^a   Tokunaga, Takatoshi ^a   Shimohigashi, Yasuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Docking calculation; Endocrine disruptor; Estrogen receptor

Indexed keywords

4 (1 ADAMANTYL)PHENOL; CELL NUCLEUS RECEPTOR; ENDOCRINE DISRUPTOR; ESTROGEN RECEPTOR ALPHA; ORGANOSILICON DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; FILM; LIGAND BINDING; MOLECULAR DOCKING; NANOPORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; REPORTER GENE;

ADAMANTANE; DIETHYLSTILBESTROL; ENDOCRINE DISRUPTORS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; HUMANS; LIGANDS; LUCIFERASES; MODELS, MOLECULAR; PHENOLS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 70350589114     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.08.001     Document Type: Article

References (23)

1. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
2. Celik L., Davey J., Lund D., and Schiott B. Exploring interactions of endocrine-disrupting compounds with different conformations of the human estrogen receptor alpha ligand binding domain: a molecular docking study. Chem. Res. Toxicol. 21 (2008) 2195-2206
3. Cha B.J., Kim S., Char K., Lee J.-K., Yoon D.Y., and Rhee H.-W. Nanoporous organosilicate thin films prepared with covalently bonded adamantylphenol pore generators. Chem. Mater. 18 (2006) 378-385
4. Cui J., Shen X., Yan Z., Zhao H., and Nagahama Y. Homology-modeled ligand-binding domains of medaka estrogen receptors and androgen receptors: a model system for the study of reproduction. Biochem. Biophys. Res. Commun. 380 (2009) 115-121
5. DeLean A., Munson P.J., and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235 (1978) E97-102
6. Endo Y., Iijima T., Yamakoshi Y., Yamaguchi M., Fukasawa H., and Shudo K. Potent estrogenic agonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. J. Med. Chem. 42 (1999) 1501-1504
7. Fukuzawa K., Kitaura K., Nakata K., Kaminuma T., and Nakano T. Fragment molecular orbital study of the binding energy of ligands to the estrogen receptor. Pure Appl. Chem. 75 (2003) 2405-2410
8. Fukuzawa K., Kitaura K., Uebayasi M., Nakata K., Kaminuma T., and Nakano T. Ab initio quantum mechanical study of the binding energies of human estrogen receptor alpha with its ligands: an application of fragment molecular orbital method. J. Comput. Chem. 26 (2005) 1-10
9. Germain P., Staels B., Dacquet C., Spedding M., and Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58 (2006) 685-704
10. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., and Gustafsson J.A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87 (2007) 905-931
11. Hong H., Tong W., Fang H., Shi L., Xie Q., Wu J., Perkins R., Walker J.D., Branham W., and Sheehan D.M. Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ. Health Perspect. 110 (2002) 29-36
12. István Virága, Tímea Polgárb, and Keserub G.M. Functional virtual screening of estrogen receptor alpha modulators by FlexX-Pharm. J. Mol. Struct. 725 (2005) 239-242
13. Liu X., Matsushima A., Okada H., Tokunaga T., Isozaki K., and Shimohigashi Y. Receptor binding characteristics of the endocrine disruptor bisphenol A for the human nuclear estrogen-related receptor gamma. Chief and corroborative hydrogen bonds of the bisphenol A phenol-hydroxyl group with Arg316 and Glu275 residues. FEBS J. 274 (2007) 6340-6351
14. Miyawaki J., Kamei S., Sakayama K., Yamamoto H., and Masuno H. 4-tert-Octylphenol regulates the differentiation of C3H10T1/2 cells into osteoblast and adipocyte lineages. Toxicol. Sci. 102 (2008) 82-88
15. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
16. Nakai M., Tabira Y., Asai D., Yakabe Y., Shimyozu T., Noguchi M., Takatsuki M., and Shimohigashi Y. Binding characteristics of dialkyl phthalates for the estrogen receptor. Biochem. Biophys. Res. Commun. 254 (1999) 311-314
17. Nose T., and Shimohigashi Y. A docking modelling rationally predicts strong binding of bisphenol A to estrogen-related receptor gamma. Protein Pept. Lett. 15 (2008) 290-296
18. Olefsky J.M. Nuclear receptor minireview series. J. Biol. Chem. 276 (2001) 36863-36864
19. Schmieder P., Mekenyan O., Bradbury S., and Veith G. QSAR prioritization of chemical inventories for endocrine disruptor testing. Pure Appl. Chem. 75 (2003) 2389-2396
20. Selassie C.D., Garg R., and Mekapati S. Mechanism-based QSAR approach to the study of the toxicity of endocrine active substances. Pure Appl. Chem. 75 (2003) 2363-2373
21. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
22. Tabira Y., Nakai M., Asai D., Yakabe Y., Tahara Y., Shinmyozu T., Noguchi M., Takatsuki M., and Shimohigashi Y. Structural requirements of para-alkylphenols to bind to estrogen receptor. Eur. J. Biochem. 262 (1999) 240-245
23. Takayanagi S., Tokunaga T., Liu X., Okada H., Matsushima A., and Shimohigashi Y. Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity. Toxicol. Lett. 167 (2006) 95-105